• Cornerstone AI

  Participated · Equity · Oct 2024

  Cornerstone AI develops AI software to clean, prepare, and analyze real-world healthcare data, automating identification and correction of inconsistencies and filling missing data. Its solution learns dataset structures and relationships, creates models for each data point, and exports clean data with a complete audit trail. The company says its tools streamline healthcare data management to improve efficiency and accuracy for biopharma and healthcare customers. Cornerstone is based in San Francisco and was founded in 2019. Leadership is shifting as Viraj Narayanan will become CEO while founder Michael Elashoff transitions to Chief Science Officer to focus on AI algorithm development. With the new capital the company plans to enhance its data processing solutions. Cornerstone AI builds automated software that structures and corrects healthcare data to accelerate data analysis and medical research. Its platform uses self-learning AI methods and includes a regulatory-grade audit trail. The product enables teams to use more patients and more data points for more precise analyses. Cornerstone is already working with companies across multiple medical areas, data sources and volumes, and customers have reported outstanding results. Led by CEO Michael Elashoff, the company plans to use new funding to further product development and scale the business to meet demand. The company is based in San Francisco, CA.

• Macro Trials

  Participated · Seed · Jul 2023

  Macro Trials offers a turnkey, digitally powered clinical research platform built around a distributed hub-and-spoke model that supports in-person and decentralized trials. The platform equips physician groups and independent clinicians with workflow-native efficiency tools, clinical research personnel, logistics partners, and real-time data collection and management. Macro aggregates and synthesizes proprietary real-world evidence to create longitudinal patient records and accelerate research velocity. The company emphasizes equitable enrollment and reports strong diversity metrics from its early trials: more than 75% female participants (vs. 41% industry standard), age disparity under one year (vs. typical 7–10 years), and 46% Hispanic participants (vs. ~6% typical). Macro plans to continue product development, expand clinical trial infrastructure across geographies and therapeutic areas, and scale its study execution and data generation flywheel. The company announced $6 million in seed funding to support those efforts.

• Delfi Diagnostics

  Participated · Series B · Jul 2022

  DELFI Diagnostics is a Palo Alto–based developer of blood-based cancer detection tests that use fragmentomics and advanced machine-learning methods applied to whole-genome sequencing data. The platform analyzes patterns of cell-free DNA fragments to detect chaotic signatures left by cancer cells. DELFI has commercialized FirstLook Lung, a blood test that evaluates DNA fragment patterns to indicate the presence of lung cancer. In an independent validation, FirstLook Lung demonstrated 80% sensitivity in a screening population, including early-stage detection, and a 99.8% negative predictive value. The company received an equity investment from the Merck Global Health Innovation Fund and intends to use the funds to accelerate development and commercialization of its cancer detection solutions. Led by CEO Susan Tousi, DELFI positions its fragmentomics and AI technologies as a potential high-precision, population-scale approach to early cancer detection at a disruptive price. Delfi Diagnostics has built a platform that analyzes cell-free DNA fragments across the entire genome using a proprietary, scalable whole-genome fragmentation approach. The platform is designed to enable a single, low-cost, and straightforward lab process for multiple liquid-biopsy tests and leverages machine learning to deliver high-performing results. Led by CEO and founder Victor Velculescu, the company is validating its technology for early detection of lung and other cancers in a 15,000-person prospective trial called CASCADE-LUNG. Delfi is working with multiple research institutions to develop additional applications including screening for other cancer types, multi-cancer early detection, and treatment monitoring. The company intends to use the funds raised to continue development and commercialization of single-cancer early detection, multi-cancer early detection, and treatment-monitoring blood tests. Headquarters are listed in Palo Alto, CA and Baltimore, MD. Delfi Diagnostics is a Baltimore-based company developing a new class of high-performance, affordable liquid biopsy tests for early cancer detection. Its platform leverages machine learning and genome-wide fragmentation profiles of cell-free DNA to detect evidence of tumors from a blood sample and to pinpoint tumor location. The company is applying this platform to a range of products to detect specific cancers, such as lung cancer in at-risk individuals, and to identify multiple cancers in any individual. Delfi plans to use the funding to expand its team of cancer researchers and machine learning experts and to validate its next-generation liquid biopsy technology through multiple prospective clinical studies. Financially, Delfi raised $100M in a Series A financing led by OrbiMed. The company is led by founder and CEO Victor Velculescu.

No current team members are available.